Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intravitreal Autologous Bone Marrow Stem Cells for Retinitis Pigmentosa
NCT02280135Phase 1Completed
- Sponsor
- Red de Terapia Celular
- Start
- Nov 2014
- Primary completion
- Mar 2017
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of autologous bone marrow-derived mononuclear cell in retinitis pigmentosa (RP) (2 arms), sponsored by Red de Terapia Celular. Primary endpoint: Rate of serious and non-serious adverse events related with the use of bone marrow mononuclear cells at 12 months. Started Nov 2014; status: completed.
02
Drugs
autologous bone marrow-derived mononuclear cell
03
Conditions
retinitis pigmentosa (RP)
Beyond the preview
Go deeper on NCT02280135.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02280135.